Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today. Malone, an endocrinologist specializing in diabetes, also spent 12 years in clinical practice. “Jim’s blended experience in medical practice and device development bring […]
Bigfoot Biomedical raises $55m in Series C
Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round. Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management. Get the full story at our sister site, MassDevice.
Abbott boosts support for Bigfoot Biomedical and its diabetes treatment tech
Diabetes treatment tech company Bigfoot Biomedical has raised another $45 million in the initial tranche of a Series C equity financing, with collaborator Abbott (NYSE:ABT) as the lead investor. “We are excited to announce Abbott’s deepening support of Bigfoot Biomedical with this Series C financing,” Bigfoot Biomedical CEO Jeffrey Brewer said in a news release today. […]
Bigfoot Biomedical inks deal with Pittsburgh health system
Bigfoot Biomedical today announced an agreement with Pittsburgh-based Allegheny Health Network (AHN) to further develop Bigfoot’s Unity investigational insulin delivery wireless platform. The diabetes startup described Unity as a first-in-kind, data-driven solution for optimizing insulin dosing and delivery. Bigfoot will work alongside AHN endocrinologists and primary care doctors to refine Unity’s clinical workflow features. “We understand […]
Bigfoot Biomedical, Owen Mumford ink deal for pen needles
Bigfoot Biomedical said today that it inked a commercial supply deal to include Owen Mumford‘s Pentips line of pen needles with Bigfoot’s injection system subscription bundles. Milpitas, Calif.-based Bigfoot is working on monthly subscription packages for people with insulin-requiring diabetes. The company said it selected Owen Mumford’s pen needle because of the needle’s compatibility with […]
Bigfoot Biomedical inks insulin deal with Eli Lilly
Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory […]
How Bigfoot Biomedical’s CEO wants to boost diabetes management
Jeffrey Brewer faced the biggest challenge of his life when his 7-year-old son Sean received a diabetes diagnosis in 2002: Diabetes became the new focus for Brewer’s energy. In his role as CEO at JDRF (formerly the Juvenile Diabetes Research Foundation) between 2011 and 2014, Brewer forged financial partnerships with industry to drive the development […]
Bigfoot brings Series B total to $55m with new investment from Abbott
Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas, Calif.-based company first launched. Investments from Abbott (NYSE:ABT), which has an established partnership with Bigfoot, and other new and existing investors, brought the […]
SFC Fluidics inks deal with JDRF to develop automated insulin delivery system
SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the […]
Bigfoot Biomedical raises $37m in Series B
Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor, Quadrant Capital Advisors. The Milpitas, Calif.-based company plans to use its newly-acquired funds to support product development and clinical evaluation of its automated […]
